CDKN2A and neoplasm: In this model, TMZ and BI2536 treatment prolonged the median survival of intracranial Ink4a/Arf(−/−) EGFRvIII tumor-bearing mice from 25 days (vehicle treated) to 32.5 days and 29.5 days, respectively.